Anti-Human CD5 Recombinant Antibody (5D7) (CAT#: TAB-308LC)

Figure 1 Flow cytometry measuring binding of hybridoma-produced 5D7 to human and cynomolgus monkey PBMCs.

Figure 2 ADCC assay with WT and variant anti-CD5 antibodies against Wac3CD5 target cells, using purified NK cells as effector cells. Anti-RSV IgGI was used as an isotype control.

Figure 3 ADCC activity of humanized anti-CD5 antibodies against Wac3CD5 CLL target cells. All antibodies comprise the heavy chain constant region of Hybrid_S239D/l332E.

Figure 4 Caspase activity assay demonstrating capacity of anti-CD5 antibody to mediate apoptosis against CLL cells.

Figure 5 show ADCC activity of anti-CD5 antibodies against lymphoma and leukemia cell lines.

Figure 6 In vitro depletion of T-cells in PBMCs by humanized anti-CD5 antibodies.

Figure 1 Anti-Human CD5 Recombinant Antibody (TAB-308LC) in SDS-PAGE

SDS-PAGE analysis of TAB-308LC in β-mercaptoethanol-reduced (Lane 1) and non-reduced (Lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively. And non-reduced protein migrates as about 180-275 kDa.

Figure 2 Anti-Human CD5 Recombinant Antibody (TAB-308LC) in SEC-HPLC

The purity of TAB-308LC was greater than 98% as determined by SEC-HPLC.

Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.0
Detection: UV 280 nm
Injection: 10 µl

Figure 3 Anti-Human CD5 Recombinant Antibody (TAB-308LC) in DB

Dot Blot analysis of TAB-308LC was performed by coating with human CD5 protein (His tag).

TAB-308LC incubation concentration: 2 μg/mL.

HRP conjugated Anti-Mouse IgG as a secondary antibody (1: 2000)

Figure 4 Anti-Human CD5 Recombinant Antibody (TAB-308LC) in WB

Western blot analysis of TAB-308LC was performed by loading human CD5 protein, His tag.

TAB-308LC incubation concentration: 2 ng/μL.
The secondary antibody: HRP-Goat Anti-Mouse IgG (H+L).

Lane 1: Reducing Antigen (0.1 μg)
Lane 2: Reducing Antigen (0.3 μg)
Lane 2: Reducing Antigen (0.6 μg)

Figure 5 Anti-Human CD5 Recombinant Antibody (TAB-308LC) in ELISA

ELISA analysis of TAB-308LC was performed by coating with human CD5 protein (His tag). Then blocked with BSA and incubated with TAB-308LC. The HRP conjugated Anti-Mouse IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 6 Anti-Human CD5 Recombinant Antibody (TAB-308LC) in FACS

Flow cytometry analysis of hPBMC cells incubated with Anti-Human CD5 Recombinant Antibody, Cat# TAB-308LC. hPBMC cells were stained with TAB-308LC (blue histogram, TE232276-1) or isotype control antibody (yellow histogram), followed by FITC-conjugated goat anti-Mouse IgG secondary antibody. The used concentration of TAB-308LC was 5 µg per 5 x 10^6 cells.